The products are based on a combination of mushrooms and cannabinoids that have achieved a strong therapeutic effect using low concentrations of THC. The treatment is expected to be launched in Israel, US and UK in H2 2022
N Yuvraj, Joint Secretary, Dept of Pharmaceuticals, Satish Reddy, Chairman, Dr Reddy’s Laboratories; Kiran Mazumdar Shaw, Executive Chairperson, Biocon Group; Sanjiv Navangul, MD & CEO, Bharat Serums and Vaccines and Shravil Patel, MD, Zydus Lifesciences discuss the way forward for the India pharma industry
PSCI, a global non-profit organization, works with its members to ensure a positive environment that can improve global healthcare supply chains
Jardiance is the first and only heart failure therapy to demonstrate a statistically significant risk reduction in cardiovascular death or hospitalization for heart failure, regardless of ejection fraction
Methodology developed by QIMR Berghofer researchers utilizing the Agilent Cary 630 FTIR
Dr. Shah will lead strategic and operational clinical development of the company's diverse pipeline
Appoints Dr Rafiq Hasan as CEO
he financing was significantly oversubscribed with high demand from both existing and new investors.
Bangladesh, Indonesia, Pakistan, Serbia and Vietnam to receive mRNA technology from the technology transfer hub
AIIA partners with Startup India with the aim to identify and support innovations and start-ups working in the Ayush sector
Subscribe To Our Newsletter & Stay Updated
